超级碰在线-超级碰碰永久免费视频播放-超级碰碰碰免费视频播放-超级碰碰碰免费视频-亚洲国产99在线精品一区69堂-亚洲高清资源在线观看

美國AmProtein   
AmProtein由Amgen前蛋白質生產科學家Matthew Hui博士創建于2002年。
AmProtein發現了以DNA物理結構為基礎的所有真核細胞通用的基因表達機制，無鼓泡的新型傳氧機制，為現代生物技術做出了巨大貢獻。

AmProtein將以DNA物理結構為基礎的真核細胞通用基因表達機制此種機制定義為“GC-rich方法”。它將引領基因擴增后第二次生物革命，并帶領世界商業化生物研究進入一個全新的領域。基于這種GC-rich方法，AmProtein發展出一套應用于哺乳動物細胞，雞細胞，魚細胞和可能的植物細胞基因表達載體并將其商業化，僅僅通過一些實驗室規模的穩定的基因轉染便可得到商業需求水平的蛋白質濃度。

基于無鼓泡式新型傳氧機制，AmProtein成功開發出一次性生物工藝用塑料袋并已作商業化生產，可為高密度細胞提供高效溶氧的培養條件。在此基礎上，AmProtein成功的衍生出了一套高密度細胞灌注培養系統。我們采用一次性的細胞貼壁紙片材料，并且使用懸浮培養系統作為溶氧生成器。

AmProtein將其高效表達系統應用于雙體藥物開發和快速生產，這將是生物技術的一次突破。AmProtein的載體系列和蛋白生產平臺是快速發展重組蛋白、抗體、基因藥物的理想選擇。

AmProtein的表達載體和反應器系列均擁有世界專利，可根據客戶需求提供相應許可。AmProtein擁有雄厚的科研力量，我們接受合同服務承接各大公司的項目及課題。

AmProtein將對全世界開放，尋求高瞻遠矚的合作者共同開發技術。目前我們在中國和美國的合作者都已開始分享AmProtein的技術帶來的豐碩果實，我們在中國的合作者包括哈藥集團，華北制藥，西安新藥中心，杭州安瑞普生物科技有限公司www.amprotein-china.com。在美國，AmProtein是加利福尼亞生物技術研究協會的成員，該技術研究協會由著名的前Amgen公司的科學家組成，更多信息請登陸：www.calbioresearch.com
AmProtein和華北制藥集團新藥研究中心、哈爾濱制藥集團技術中心、哈藥生物以及西安新藥評價研究中心形成緊密的技術和生產聯盟,以杭州為中心,已形成一個國際生物高技術平臺,為中國奠定了生物工業基礎。

AmProtein由六大功能區組成，其中五個研究方向是基于AmProtein在基因表達和傳氧機制的重大世界性突破。我們的專利和概念已經擴展為橫跨多個生物技術工程領域的一整條產業鏈。

AmProtein家族：

● 生物反應器&培養基

1、激流式懸浮&灌注生物反應器系統

2、模擬反應器系統

3、配套附件

● 表達系統

1、用于哺乳動物，魚&雞的pMH3-5 載體系列

2、來源于植物的載體系列正在研發中

● 醫療設備

“人工肺”心臟旁路溶氧生成器用于安全的長時間全血細胞培養&傳氧

● 疫苗

1、關于哺乳動物，魚和雞疫苗生產高密度細胞培養工藝的突破

2、關于人類疫苗生產高密度細胞培養工藝的突破

● 治療&合同服務

1、雙體藥物

2 、Hyper-G融合技術（取代Pegylation方法）

3、改制藥與改制藥仿制

● 市場

全球商業數據庫

 
AmProtein is a biotech company founded in 2002 by Matthew Hui, MD, PhD, formerly a key protein production scientist at Amgen. AmProtein has developed a reputation as a biotechnology powerhouse that has revolutionized the modern biotechnology industry with the discovery of a DNA physical structure-based gene expression mechanism, common to all eukaryotic cells, and a novel, non-sparging-dependent O2 transfer method.

AmProtein has termed this mechanism the 'GC-rich method.' It has led to a second revolution after the gene amplification method, and has surely resulted in a new era in commercialized biologics research worldwide. Based on the GC-rich method, AmProtein has developed and commercialized a gene expression vector series for mammalian cells, chicken cells, fish cells, and possibly plant cells. By using the GC-rich method, one can reach commercial level protein titers after only a few laboratory-scale stable gene transfections.

Based on the above non-sparging O2 transfer method, we have successfully commercialized a single-use, plastic bag-based bioreactor series as an effective dissolved oxygen (DO) generator for high-density suspension cell culture.

In addition, AmProtein has successfully developed a high-density perfusion cell culture system by using a single-use, cell attachment paper-carrier material and our suspension culture system as a DO generator.

AmProtein has applied its expression system for the rapid production and subsequent development of our dual domain drug product candidates, the next IP frontier in biologics. AmProtein's vector series and protein production platform are ideal for the rapid development of recombinant protein, antibody, and generic drugs. Both AmProtein's revolutionary expression vector and superior bioreactor series are available for licensing. Also, AmProtein has the capability to support the projects of other companies through its Contract Research division.

AmProtein is open to fostering partnerships around the globe for the co-development of its technologies. Currently we enjoy fruitful collaborations is China and the United States. Our partners in China include Harbin Pharmaceutical Group Corporation, North China Pharmaceutical Corporation, Xian Drug Evaluation Center, and Hangzhou AmProtein Biotechnology Co., Ltd. www.amprotein-china.com. In America, AmProtein is a part of the California Biotechnology Research Consortium. The Consortium consists of companies started by well-known ex-Amgen scientists. See www.calbioresearch.com for more information.